Esflurbiprofen transdermal

Drug Profile

Esflurbiprofen transdermal

Alternative Names: LOQOA Tape; S-Flurbiprofen; S-flurbiprofen transdermal; SFPP; TT-063

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Tokuhon Corporation
  • Developer Taisho Pharmaceutical; Tokuhon Corporation
  • Class Analgesics; Antirheumatics; Nonsteroidal anti-inflammatories; Propionic acids
  • Mechanism of Action Cyclo-oxygenase 1 inhibitors; Cyclo-oxygenase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Osteoarthritis
  • No development reported Inflammation; Muscle pain; Periarthritis

Most Recent Events

  • 26 Sep 2016 Taisho Pharmaceutical completes a phase II trial for Pain (in patients with knee osteoarthritis) in Japan (Transdermal) before September 2016 (JapicCTI090907)
  • 21 Jan 2016 Launched for Osteoarthritis in Japan (Topical)
  • 28 Sep 2015 Registered for Osteoarthritis in Japan (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top